Overview

The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors

Status:
Active, not recruiting

Trial end date:
2024-03-28

Target enrollment:

Participant gender:

Summary

Open label, single- and multiple-dose administration, dose-exploratory clinical phase I study to evaluate the safety, tolerability and PK profile of HX301 monolactate capsules in patients with advanced malignant solid tumors and to preliminarily evaluate its antitumor efficacy.

Phase:

Phase 1

Details

Lead Sponsor:

Hangzhou Hanx Biopharmaceuticals, Ltd.

Collaborator:

Wuhan Hanxiong Bioscience, Ltd.